Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573370 | 1.00 | CYP1A1 (0.58) | CYP1A1CYP1B1NFE2L2HSD11B1MIF | |
| SCHEMBL9907017 | 0.88 | GSK3B (0.53) | CYP1A1CYP1B1NFE2L2HSD11B1MIF | |
| SCHEMBL29407005 | 0.86 | MIF (0.71) | CYP1A1CYP1B1NFE2L2MIFPTGS1 | |
| SCHEMBL716629 | 0.86 | MIF (0.71) | CYP1A1CYP1B1NFE2L2MIFPTGS1 | |
| SCHEMBL1920415 | 0.86 | MIF (0.71) | CYP1A1CYP1B1NFE2L2MIFPTGS1 | |
| SCHEMBL716630 | 0.86 | MIF (0.71) | CYP1A1CYP1B1NFE2L2MIFPTGS1 | |
| Hydrochloric Acid SCHEMBL6822230 | 0.85 | MIF (0.69) | CYP1A1CYP1B1NFE2L2MIFPTGS1 | |
| SCHEMBL5751280 | 0.85 | CYP1A1 (0.55) | CYP1A1CYP1B1NFE2L2MIFPTGS1 | |
| SCHEMBL6822226 | 0.85 | CYP1A1 (0.55) | CYP1A1CYP1B1NFE2L2MIFPTGS1 | |
| SCHEMBL6822228 | 0.85 | CYP1A1 (0.55) | CYP1A1CYP1B1NFE2L2MIFPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2004-09-09 | — | — | US | claimed |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2002-02-14 | — | — | US | claimed |
| US-7842705-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | EMORY UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| US-7371766-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2008-05-13 | — | — | US | disclosed |
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2004-09-09 | — | — | US | disclosed |
| US-6664272-B2 | Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue | EMORY UNIVERSITY | 2003-12-16 | — | — | US | disclosed |
| EP-1242379-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | Emory University (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040188-A9 | CURCUMIN ANALOGUES FOR TREATING CANCER | UNIV EMORY (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2002-02-14 | — | — | US | disclosed |
| WO-2001040188-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | EMORY UNIVERSITY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | CYP1A1 4406/4885CYP1B1 4023/4885NFE2L2 137/4885 |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | PGF, VEGFA, VHL | CYP1A1 4406/4885CYP1B1 4023/4885NFE2L2 137/4885 |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | CYP1A1 4406/4885CYP1B1 4023/4885NFE2L2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.